Jason Kropp has built a substantial practice advising local, national and international clients on their most critical and complex business needs and transactions. As partner in the Corporate Practice Group and member of the firm’s Management Committee, Mr. Kropp practices corporate and securities law, with an emphasis on public offerings and public company representation, and representation of emerging and growth-stage companies and venture capital and late-stage investors. Mr. Kropp represents clients across industry sectors, including biotechnology, pharmaceuticals, medical devices and software, among others.

Practice

A significant portion of Mr. Kropp's practice consists of counseling public companies in ongoing corporate legal matters, including federal securities reporting requirements and corporate governance issues. He represents issuers and underwriters in capital markets financings, including initial public offerings, follow-on equity offerings and convertible debt offerings. Mr. Kropp advises public and private companies at all stages on the range of issues they face, and he represents investors and issuers in initial- and late-stage investments. Learn more about how Mr. Kropp can support your startup on WilmerHaleLaunch.com.

Prior to attending law school, Mr. Kropp worked as a legislative and press aide in the office of United States Representative William Delahunt, and as a legislative intern in the office of United States Representative Gerry Studds.

Community Involvement

Mr. Kropp represents pro bono clients Grist.org, an online environmental news and opinion magazine, and the Animal Rescue League of Boston, which provides a variety of services aimed at animals in need. He is also a member of the Board of Directors of Coaching4Change, whose innovative model creates opportunities for high school students to improve their math, literacy and leadership skills by turning them into coaches and teachers of younger kids.

Experience

  • Select Investments

    • ImmPact Bio in its $111 million Series B financing
    • Esme Learning Solutions in its $15 million Series A financing
    • Exo Therapeutics in its $78 million Series B financing
    • GentiBio in its $157 million Series A financing
    • Corvia Medical in its $35 million strategic investment by Edwards Lifesciences
    • Myeloid Therapeutics with respect to more than $50 million in financing
    • VDYNE in its $21 million Series C financing
    • A growth-stage investor in the $175 million Series D financing of Material Bank
    • A growth-stage investor in the $106 million Series C financing of Capital Rx
    • A growth-stage investor in the $85 million Series D financing of OM1
    • A growth-stage investor in the $190 million Series C financing of Maze Therapeutics
    • A global, institutional investor in the $200 million Series E financing of Synthego 
    • A global, institutional investor in the $380 million Series C financing of Course Hero 
    • A global, institutional investor in the $300 million Series E financing of SpotOn
    • A global, institutional investor in the $260 million Series D financing of Greenlight Financial
    • A global, institutional investor in the $186 million Series E financing of Olist
    • A global, institutional investor in a $1.2 billion preferred stock financing of Uber Technologies 
    • A global, institutional investor in a $112 million preferred stock financing of One Kings Lane
    • A global, institutional investor in an investment in Payoneer
    • A global, institutional investor in the $150 million Series C financing of Dewpoint Therapeutics
    • A global, institutional investor in several financings of DraftKings and its merger of equals with FanDuel
    • Numerous financial and strategic investors, including General Catalyst Partners, Samsara BioCapital, OrbiMed, RA Capital, Novartis Venture Fund, Matrix Partners, New Leaf Venture Partners, and Sofinnova Ventures, among others, in private placement financings
    • Dozens of private companies in various venture capital financings
  • Select M&A Transactions

    • Acacia Communications, Inc. in its acquisition by Cisco Systems, Inc. for $3.1 billion in cash and assumed equity awards
    • ASICS Corporation in its acquisition of FitnessKeeper
    • Corvia Medical in its exclusive option-to-purchase transaction with an undisclosed strategic partner
    • ABRY Partners in its acquisition of NSM Insurance
    • NSM Insurance in its sale to American International Group, Inc. 
    • Link Medicine in its sale of neuroscience assets to AstraZeneca
    • ImmPACT Bio in its acquisition of Kalthera
    • InfoMedics in its sale to Physicians Interactive 
    • Jebbit in its sale to Vista Equity Partners
    • Kiva Systems in its $775 million acquisition by Amazon.com
    • General Catalyst in the sale of portfolio company Locu to GoDaddy
    • EqualLogic in “dual track” IPO/sale, resulting in $1.4 billion acquisition by Dell—then the largest cash purchase price in history for a private VC-backed company
    • Millennium Pharmaceuticals in its $8.8 billion acquisition by Takeda Pharmaceuticals
    • Lucent Technologies Inc. in its acquisition of assets of Riverstone Networks, Inc.; DoubleClick in its acquisition by Hellman & Friedman;
    • Amdocs Limited in its acquisitions of Qpass Inc. and DSTInnovis from DST Systems, Inc.
    • ZeroNorth in its sale to Harness
  • Select Capital Markets Transactions

    • Ameresco in its $140 million public offering of common stock
    • EverQuote in its $85 million IPO
    • Acacia Communications in its $119 million IPO and $450 million follow-on public offering
    • Karyopharm in its $114 million follow-on public offering of common stock
    • Epizyme in its $150 million follow-on public offering of common stock
    • Demandware in its $73 million follow-on public offering of common stock
    • Endurance International Group in its $252 million initial public offering and $189 million and $264 million follow-on offerings 
    • Ameresco, Accretive Health, LogMeIn, Cynosure and Eyetech Pharmaceuticals in their initial public offerings
    • Deutsche Bank Securities as lead underwriter in the initial public offering of Targacept, Inc.
    • Amdocs Limited, LIN TV Corp. and Lincare Holdings in 144A offerings of convertible notes
    • Morgan Stanley as lead underwriter in follow-on public offering of common stock by Barrier Therapeutics, Inc

Recognition

  • Recognized in the 2015–2022 editions of Chambers USA: America's Leading Lawyers for Business for his Corporate/M&A practice, with sources describing him as "really phenomenal in the corporate and securities area" and that "he has a great temperament, he's a great negotiator and he keeps his cool in situations."
  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021 in the area of corporate law.
  • Recommended in the area of M&A: Middle-Market and Venture Capital and Emerging Companies in the 2018 and 2019 editions of The Legal 500 United States.
  • Recognized as a 2014 Boston Rising Star by The National Law Journal, a list honoring 40 outstanding lawyers aged 40 or under who "have accomplished big feats" and are also "improving their communities." 
  • Named to M&A Advisor's 2014 "40 Under 40" list.
  • Named a 2013–2016 "Massachusetts Super Lawyers' Rising Star" in the area of business/corporate.
  • Recognized as a 2011 "Up & Coming Lawyer" by Massachusetts Lawyers Weekly.

Insights & News

Credentials

  • Education

    • JD, Boston College Law School

    • BA, The George Washington University

  • Admissions

    • Massachusetts

    • New York

Credentials